| Drug Name |
Valbenazine |
| Drug ID |
BADD_D02491 |
| Description |
Valbenazine (development name NBI-98854) has been used in trials studying the treatment and basic science of Tourette Syndrome and Tardive Dyskinesia. In April, 2017, valbenazine was approved by the FDA (as Ingrezza) as the first and only approved treatment for adults with Tardive Dyskinesia (TD). |
| Indications and Usage |
For the treatment of tardive dyskinesia in adults [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
N07XX13 |
| DrugBank ID |
DB11915
|
| KEGG ID |
D10675
|
| MeSH ID |
C000603978
|
| PubChem ID |
24795069
|
| TTD Drug ID |
D63WMQ
|
| NDC Product Code |
47049-021; 66406-0314; 70370-2040; 70370-2048; 47049-008; 47049-009; 70370-1060; 70370-1080; 66406-0274 |
| UNII |
54K37P50KH
|
| Synonyms |
valbenazine | (2R,3R,11BR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl l-valinate | NBI-98854 | Ingrezza | valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester |
